A series of di-and triorganotin 3,6-dioxaheptanoates and 3,6,9- 
Introduction
Many di-n-butyl, tri-n-butyl and triphenyltin carboxylates display interesting antitumour activities in vitro against tumour cell lines of human origin [1, 2] . As early as 1985, Atassi suggested that the usually low water solubility of organotin compounds might be the major drawback to the improvement of their antitumour properties [3] . One possibility to increase water solubility is to replace methylene groups in a polymethylenic chain by oxygen atoms [4] . Accordingly, some new organotin derivatives of 3,6-dioxaheptanoic and 3,6,9-trioxadecanoic acid were synthesized. This report presents their synthesis, characterization and in vitro antitumour activity.
Results and discussion Synthesis
For the triorganotin polyoxaalkanoates, the condensation is carried out in benzene using triphenyltin hydroxide respectively tri-n-butyltin acetate and either 3,6-dioxaheptanoic or 3,6,9-trioxadecanoic acid (equations and 2) [2] [3] [4] [5] .
(C6H5)3SnOH + RCOOH (C6H5)3SnOCOR + H20
(1) Bu3SnOCOCH3 + RCOOH Bu3SnOCOR + CH3COOH
(2) For the diorganotin polyoxaalkanoates, di-n-butyltin oxide first reacts with n-propanol to form tetrabutyldipropoxydistannoxane ( [7] . (7, 7) CH3 (6) 0.88
0.87
0.8-0.9 m CH2 (5) 3.6-3.7 m 3.6-3.8 m 3.6-3.8 m CH2 (7) 3.5-3.6 m 3.6-3.8 m 3.6-3.8 m CH2 (8) 3 (7) 0.88 [102] (7, 7) 
M6ssbauer spectroscopy
The Mtssbauer parameters are shown in CH3 (5) 13.6 13.5 13.6 Tables and 2) .
In vitro antitumour screening
All compounds were screened against seven tumoural cell lines of human origin.
The IDs0 values are reported in Table 9 and compared to those of some drugs with clinical applications and of organotin carboxylates containing crown ether moieties: di-n-butyl, tri-n-butyl and triphenyltin derivatives of 4-carboxybenzo-18-crown-6 and -15-crown-5 [11] of which the structures are depicted in figure 2 . Diorganotin carboxylates Di-n-butyltin oxide is allowed to react with 1-propanol (typically g of di-butyltin oxide and 4 ml of 1-propanol) in benzene (250 ml) in a 500 ml three-necked flask. The reaction mixture is refluxed for 3 hours under elimination of the ternary azeotrope benzene/water/1-propanol (Dean-Stark). After cooling to room temperature, the appropriate amount of polyoxaalkanecarboxylic acid (1/1 molar ratio polyoxaalkanecarboxylic acid / di-n-butyltin oxide for 3 and 7; 2/lmolar ratio for 4 and 8) is added slowly and the mixture is stirred overnight. The solvent is then evaporated and the product treated as indicated in Table 10 in which all experimental synthesis details are summarized.
NMR measurements All 2D NMR spectra and some of the 1D spectra were recorded on a Bruker AMX500 spectrometer interfaced with a X32 computer and operating at 500. 13 [2, 3] . 2D gradient enhanced IH-3C HMQC [14] and HMBC [5] correlation spectra were acquired using the pulse sequences of the Bruker program library, adapted to include gradient pulses,[ 619] as described recently [2] .
MOssbauer spectroscopy The M6ssbauer spectra were recorded as described elsewhere [2] .
Mass spectrometry
The electrospray mass spectra were recorded in the cationic mode on a Micromass Quattro II instrument coupled with a Masslynx system (ionisation in an electric field of 3,5 kV; source temperature: 80C; source pressure: atm; analyzer pressure: 10 -5 mbar) [ 22, 23] . Cone voltages were 30 V for compounds 1 to 3 and 5 to 7, and 70 V for compounds 4 and 8.
Antitumour screening
The protocol followed for the antitumour screenings has already been reported [24, 25] .
